Managing Treatment-Resistant Depression
Road to Novel Therapeutics
- 1st Edition - March 31, 2022
- Latest edition
- Editors: Joao L. de Quevedo, Patricio Riva-Posse, William V. Bobo
- Language: English
Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurob… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD.
Key features
Key features
- Defines Treatment-Resistant Depression and Staging Treatment Intensity
- Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions
- Discusses the use of Ketamine and Esketamine for treatment-resistant depression
Readership
Readership
Advanced students and researchers in neuroscience, psychology, medicine, health sciences, and pharmacology
Table of contents
Table of contents
1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity
2. Clinical and epidemiological predictors of treatment-resistant depression
3. The economic burden of treatment-resistant depression: Cost-of-illness perspective
4. The neurobiology of treatmentresistant depression
5. Modeling treatment-resistant depression in the preclinical setting
6. Treatment algorithms for treatment-resistant depression
7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
8. Tricyclic antidepressants for treatment-resistant depression
9. Monoamine oxidase inhibitors for treatment-resistant depression
10. Switching antidepressants in patients with treatment-resistant depression
11. Adjunctive strategies for treatment-resistant depression
12. Combining antidepressants to address treatment-resistant depression
13. Ketamine/esketamine for treatment-resistant depression
14. Psychedelic agents for treatmentresistant depression
15. Inflammation and treatment resistance: Mechanisms and treatment implications
16. Opioid agents for treatmentresistant depression
17. Transcranial magnetic stimulation for treatment-resistant depression
18. tDCS for treatment-resistant depression
19. ECT for treatment-resistant depression
20. MST for treatment-resistant depression
21. VNS for treatment-resistant depression
22. Deep brain stimulation for treatment-resistant depression
23. Other neurosurgical interventions for treatment-resistant depression
24. Treatment-resistant psychotic depression
25. Evidence-based psychotherapy for treatment-resistant depression
26. Treatment-resistant bipolar depression
27. Treatment-resistant depression in child and adolescents
28. Treatment-resistant depression in geriatrics
29. Identification and management of anxious depression in patients with treatment-resistant depression
30. Managing treatment-resistant depression with comorbid personality disorders
31. Managing treatment-resistant depression with comorbid substance use disorders
32. Managing treatment-resistant depression in the setting of chronic pain
33. Inhaled gases for treatmentresistant major depression
34. Drugs under investigation for treatment-resistant depression
35. Chronotherapeutics for treatmentresistant depression
36. Managing treatment resistant depression in primary care settings
37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
38. Lifestyle interventions for treatment-resistant depression
39. Managing the risk of suicide in people with treatment-resistant depression
40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression
2. Clinical and epidemiological predictors of treatment-resistant depression
3. The economic burden of treatment-resistant depression: Cost-of-illness perspective
4. The neurobiology of treatmentresistant depression
5. Modeling treatment-resistant depression in the preclinical setting
6. Treatment algorithms for treatment-resistant depression
7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
8. Tricyclic antidepressants for treatment-resistant depression
9. Monoamine oxidase inhibitors for treatment-resistant depression
10. Switching antidepressants in patients with treatment-resistant depression
11. Adjunctive strategies for treatment-resistant depression
12. Combining antidepressants to address treatment-resistant depression
13. Ketamine/esketamine for treatment-resistant depression
14. Psychedelic agents for treatmentresistant depression
15. Inflammation and treatment resistance: Mechanisms and treatment implications
16. Opioid agents for treatmentresistant depression
17. Transcranial magnetic stimulation for treatment-resistant depression
18. tDCS for treatment-resistant depression
19. ECT for treatment-resistant depression
20. MST for treatment-resistant depression
21. VNS for treatment-resistant depression
22. Deep brain stimulation for treatment-resistant depression
23. Other neurosurgical interventions for treatment-resistant depression
24. Treatment-resistant psychotic depression
25. Evidence-based psychotherapy for treatment-resistant depression
26. Treatment-resistant bipolar depression
27. Treatment-resistant depression in child and adolescents
28. Treatment-resistant depression in geriatrics
29. Identification and management of anxious depression in patients with treatment-resistant depression
30. Managing treatment-resistant depression with comorbid personality disorders
31. Managing treatment-resistant depression with comorbid substance use disorders
32. Managing treatment-resistant depression in the setting of chronic pain
33. Inhaled gases for treatmentresistant major depression
34. Drugs under investigation for treatment-resistant depression
35. Chronotherapeutics for treatmentresistant depression
36. Managing treatment resistant depression in primary care settings
37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
38. Lifestyle interventions for treatment-resistant depression
39. Managing the risk of suicide in people with treatment-resistant depression
40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression
Review quotes
Review quotes
*4 stars* "...presents a comprehensive, extensive Review of the current understanding of depression, its epidemiology, presentation, predictors, socioeconomic burden, neurobiology, and effectiveness of pharmacotherapy and nonpharmacological and psychotherapeutic interventions. This book extensively reviews the current understanding of treatment-resistant depression (TRD), covering a wide variety of topics including disease burden, presentation, and course…. [A]ppropriate for a broad audience,… covers a broad range of topics across 500-plus pages and 40 chapters,… a resource that should be on the shelves of those managing this complicated and challenging population.” —©Doody’s Review Service, 2023, Michael Easton, MD (Rush University Medical Center)
Product details
Product details
- Edition: 1
- Latest edition
- Published: March 31, 2022
- Language: English
About the editors
About the editors
JQ
Joao L. de Quevedo
Dr. João Luciano de Quevedo, MD, PhD, is a Professor of Psychiatry at the McGovern Medical School, the University of Texas Health Science Center at Houston, where he is the Vice-Chair for Faculty Development and Outreach, Director of the Translational Psychiatry Program, and Director of the Treatment-Resistant Depression Clinic. Before moving to Houston, he was a Dean at the University of Southern Santa Catarina Medical School, Criciúma, SC, Brazil, where he is still an Adjunct Professor of Psychiatry. He is also Editor-in-Chief of the Brazilian Journal of Psychiatry and Director of the Continuous Medical Education Program in Psychiatry (PROPSIQ) of the Brazilian Psychiatric Association. Dr. Quevedo’s research interest is neurobiology of psychiatric disorders, particularly mood disorders, and he is a specialist in both unipolar and bipolar treatment–resistant depression. He is author of nearly 600 publications and 10 scientific books.
Affiliations and expertise
Professor of Psychiatry at the McGovern Medical School, The University of Texas Health Science Center at Houston, TX, USAPR
Patricio Riva-Posse
Dr. Patricio Riva-Posse, MD is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. After completing his training in Neurology and in Psychiatry, he has focused his clinical and research work in the field of treatment resistant mood disorders. He is the Director of the Treatment Resistant Depression Clinic, and Director of Neuromodulation Services. He conducts research in invasive and non-invasive neuromodulation as well as novel pharmacological approaches. He is an investigator in NIH-funded project studying subcallosal cingulate deep brain stimulation. Born in Argentina, he earned his Medical Doctor degree from the Universidad de Buenos Aires.
Affiliations and expertise
Emory University, Atlanta, GA, USAWB
William V. Bobo
Dr. William V. Bobo, M.D., M.P.H., is Professor of Psychiatry at the Mayo Clinic Alix School of Medicine and Chair, Department of Psychiatry & Psychology at Mayo Florida, where he also serves as the Medical Director for Leadership Development. His clinical and research interests are focused on the treatment of patients with refractory mood disorders and on examining and predicting the clinical effects — both beneficial and harmful--of medications used to treat people with severe mood disorders. He lives with his wife in Jacksonville, Florida.
Affiliations and expertise
Mayo Clinic, Jacksonville, FL, USAView book on ScienceDirect
View book on ScienceDirect
Read Managing Treatment-Resistant Depression on ScienceDirect